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Abstract
More than a thousand disease susceptibility loci have been identified via genome-wide association
studies (GWAS) of common variants; however, the specific genes and full allelic spectrum of
causal variants underlying these findings generally remain to be defined. We utilize pooled next-
generation sequencing to study 56 genes in regions associated to Crohn’s Disease in 350 cases and
350 controls. Follow up genotyping of 70 rare and low-frequency protein-altering variants (MAF
~ .001-.05) in nine independent case-control series (16054 CD patients, 12153 UC patients, 17575
healthy controls) identifies four additional independent risk factors in NOD2, two additional
protective variants in IL23R, a highly significant association to a novel, protective splice variant in
CARD9 (p < 1e-16, OR ~ 0.29), as well as additional associations to coding variants in IL18RAP,
CUL2, C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by providing
novel, rare, and likely functional variants that will empower functional experiments and predictive
models.
Crohn’s disease (CD) and ulcerative colitis (UC) are classified as chronic, idiopathic
inflammatory bowel diseases (IBD) of the gastrointestinal tract with unknown etiology
(IBD: OMIM #266600). CD is prevalent in roughly 100–150 per 100,000 individuals of
European ancestry1. Generally, the disease affects the ileum and colon but can affect any
region of the gut. UC has similar population prevalence and although shows some
similarities in clinical manifestation, the location of inflammation is limited to the colonic
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mucosa. Strong familial aggregation has been seen in twin studies of CD and UC. Recent
population-based sibling risk is 26-fold greater for CD and 9-fold greater for UC, and
overall CD and UC concordance rates in non-selected twin studies is 30% and 15%,
respectively among monozygotic (MZ) twins compared to 4% for CD or UC among
dizygotic (DZ) twins2,3. Like most complex trait diseases, CD and UC result from a
combination of genetic and non-genetic risk factors; each individual factor may be expected
to have a relatively modest effect on disease risk4.
There is a clear genetic basis to common immune-mediated diseases such as IBD. However,
until recently, identifying disease susceptibility genes was challenging for common,
polygenic disease5,6. With the development of HapMap and the GWAS technology,
complex trait genetics in general, and IBD in particular, have seen a remarkable increase in
the number of bona fide associated loci that have been identified and replicated. In CD,
individual genome-wide association scans (GWAS) and a follow-on meta-analysis of those
studies have robustly identified over 71 susceptibility loci and have provided significant
novel insights beyond the two loci that were established prior to the GWAS era7,8. Similarly
in UC, GWAS studies have identified a total of 47 susceptibility loci9,10 and, accounting for
the extensive number of alleles associated to both diseases, in total 99 distinct associations
have been documented for IBD. While these new findings have already provided novel
insight into disease pathways, the common SNPs identified are generally of modest effect
and explain only about 23% of the overall variance in CD risk. Moreover, most of the
associated variants do not have any known or obvious function and many implicate regions
with multiple genes, limiting biological extrapolation.
SNPs implicated by GWAS have tight correlation to other SNPs in the region and are most
likely to be in linkage disequilibrium with the causal variant rather than causal themselves.
A complete catalog of all variation is required in the search for causal variants11,12. Even
with denser reference data from 1000 Genomes Project however, the majority of GWAS hits
are not correlated to a coding or obvious functional variant, and therefore do not
conclusively implicate a unique gene. Should independently associated rare coding variation
be discovered in a gene within a region implicated by GWAS, the gene harboring such
variants becomes directly implicated. Furthermore, additional heritability could be explained
and specific alleles identified for direct functional experimentation. In CD, multiple
independent associated alleles are already documented at NOD2 and IL23R13,14. Exhaustive
sequencing of genomic regions has recently become feasible for the first time with the
advent of next-generation sequencing (NGS) technologies. Growing collections of genome
sequences through international efforts like the 1000 Genomes Project are driving the
development of laboratory study designs and analytic methods for utilizing large-scale
genomic sequencing in human genetic discovery15.
Targeted sequencing of pooled samples affords the opportunity to efficiently and cost-
effectively capture all variation in a more limited target region selectively amplified in
multiple DNA samples16,17. Such an approach allows efficient use of NGS technologies,
which generate billions of base pairs per experimental unit, yet introduce challenges in data
processing and analysis to discover novel variants and assess their potential association to
disease. We describe here a pooled NGS study of 350 patients with CD and 350 controls
across coding exons of 56 genes contained in regions of confirmed significant association to
CD7, and introduce novel SNP calling methods for pooled targeted sequencing projects
implemented in the software Syzygy. Novel, potentially functional rare variants identified in
the survey are then evaluated in eight independent case-control series, enabling the
confirmation of a role for functional, rare variants in CARD9 (Gene ID: 64170), NOD2
(Gene ID: 64127), IL23R (Gene ID: 149233), IL18RAP (Gene ID: 8807) as well as
additionally identifying others in MUC19 (Gene ID: 283463), CUL2 (Gene ID: 8453),
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PTPN22 (Gene ID: 26191), and C1orf106 (Gene ID: 55765) more associated than permitted
by chance. The results lend further support to an emerging paradigm seen across both rare
diseases (Hirschsprung’s disease, Bardet-Biedl syndrome) and common phenotypes (serum
lipids, QT-interval, height, Type 1 Diabetes) where both common, low-penetrance and rarer,
often higher penetrance, alleles exist in the same gene and suggest that deep sequencing of
regions implicated by GWAS may be effective in extending the heritability and knowledge
of specific functional alleles in complex disease16,18,19,20,21.
RESULTS
Discovery of new variants in patients with CD and healthy controls using pooled
sequencing
We selected 350 patient with CD and 350 healthy controls of European ancestry from
among samples collected by the NIDDK IBD Genetics Consortium (IBDGC) with genome-
wide SNP data14,22. Samples were pooled in batches of 50 cases or 50 controls matched for
European ancestry using GWAS data. One pool of 50 cases was drawn from self-reported
and empirically confirmed (by GWAS data22) Jewish ancestry and was matched with one
pool of 50 equivalently defined Jewish controls – remaining pools of cases and controls
were selected from the non-Jewish European samples. Pooling of samples was performed
only after two rounds of quantification and normalization to insure that the initial DNA pool
accurately reflected sample allele frequencies. For each pool we performed PCR
amplification to capture the 107.5 kb target of genomic region, which included 645 nuclear-
encoded exons (Table S1, S2). We amplified each sample in 593 PCR reactions and the
successful PCR amplicons were combined in equimolar amounts, concatenated, and then
sheared to construct libraries. The 14 libraries were sequenced using Illumina Genome
Analyzer flowcells, with one pool per lane (see Methods) (Figure 1a).
High-throughput sequencing yielded large amounts of high quality data for each pool. We
captured 91% of our nuclear target regions at ≥ 100X coverage and achieved 1500X median
coverage per pool (corresponding to 30X per sample/15X per individual chromosome)
(Figure S1).
We next aimed to identify rare and low frequency single nucleotide variants/polymorphisms
in the pooled samples. We developed a variant calling method (which we named Syzygy) to
accommodate the specific pooled study design and confidently identify rare variants (see
Supplementary Methods). Through empirical modeling of the sequencing error processes
and filters to remove sites with strand inconsistency or clusters of variants suggestive of read
misalignment, Syzygy detected 429 putatively high-confidence variants (240
nonsynonymous sites, 169 synonymous sites, and 20 intronic variants within 5 bp of a splice
junction) within our 107.5kb targeted region with 45% of the variants already included in
dbSNP using dbSNP version 132, nonsynonymous-to-synonymous ratio of 1.42, and
transition to transversion ratio of 2.3 (Table 1).
Given that our experimental design aimed to detect variants correctly at the limit of machine
quality, we estimated the proposed set of false positive SNPs that would need to be
eliminated in subsequent genotyping. Both the proportion of variants in dbSNP and the
transition/transversion ratio (Ti/Tv) suggest a relatively high true positive rate in this data
set. Specifically, high depth individual level sequencing of 1000 genes performed by the
1000 Genomes project (so-called ‘Pilot 3’) in 697 samples identified a high-quality SNP set
with the same %dbSNP (dbSNP version 129), while the Ti/Tv detected here suggests a
roughly 90% true positive rate23. To confirm this, a random subset of 137 high-confidence
functional nonsynonymous, nonsense, and putative splice variant SNPs was selected for
Sequenom iPLEX genotyping of all samples in the sequenced pools and 91.2% validated
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(Figure 1a). Using a canonical expectation of (theta*SUM(1..1/n)*Nbases), or the rate
observed directly in 1000Genomes Pilot 3, we would expect to see ~470 variants across the
successfully queried target. Sensitivity for singletons however is incomplete at the lower end
of coverage in our experiment (Figure S1) and readily accounts for the modest deficit in our
study.
One of the main concerns in any pooled genotyping or sequencing experiment is accurate
recovery of allele frequencies. We observed a surprisingly strong correlation between
genotype frequencies and sequence level data estimated frequencies (r2 ~ .99) using the
method in Syzygy – suggesting the accurate quantitation of DNAs in the pooling steps
resulted in good experimental recovery of the pool makeup. A strong correlation is therefore
also shown for the case-control test statistic estimated with the pooled data and the test
statistic in the genotype data (r2 ~ .925) (Figure S2).
In order to test the role of these rare variants, we identified all nonsynonymous, nonsense or
splice site variants which occurred in 2 or more copies up to a frequency of 5% - a total of
115 variants (Table S3). Excluding known GWAS associated low-frequency coding variants
at NOD2 IL23R and LRRK2/MUC19, follow-up genotyping was performed for 70 of these
markers in eight independent case control samples totaling 16054 CD disease patients,
12153 UC disease patients, and 17575 healthy controls: 1) samples from the MGH-PRISM
study, 2) samples assembled from throughout North America and Australia by the NIDDK
IBDGC, 3) an Italian-Dutch case-control sample, 4) CCFA Repository Collection, 5)
Swedish samples, 6) Cedars samples, 7) German samples as well as Immunochip genotype
data provided by 8) the International IBD Genetics Consortium and 9) UK IBD Genetics
(n.b., rare coding variants discovered in this study were contributed to Immunochip design)
(Figure 1a). Samples 1, 3, 4, and 5 were genotyped for sets of markers using Sequenom
iPLEX, Sample 2 genotyping was done as part of a larger IBDGC Illumina GoldenGate
study - because of design constraints and assay failures not all markers were examined in all
eight follow-up sample sets (see Supplementary Material online for more details of follow-
up genotyping). We demonstrate that the current study design is well positioned to address
the overall contribution of variants in coding regions of GWAS loci to IBD (Figure 1b,
Figure S3, Supplementary Material).
The small number of non-reference alleles expected for many of these variants in each sub-
study precludes the use of asymptotic statistics common to association, and the likelihood
that population structure becomes an even more significant problem at low frequencies
demands a stratified analysis where strict population case-control matching is retained. With
this in mind we implemented a mega-analysis of rare variants (MARV) that provides a
permutation-based estimate of significance, constraining all permutations to be within each
subgroup and thus accommodating arbitrary numbers of sample subsets of diverse
population and case-control origin without power loss for single marker and group marker
analysis (see Online Methods). Given a target set of 70 variants, in the follow-up analyses
we’d expect fewer than 1 SNP to exceed p < .01 by chance and would define traditional
experiment-wise significance to be p=.0007. Given both CD and UC are explored in follow-
up, to maximize power the primary analysis presented compares all IBD (CD+UC) versus
control for genes in which the same common variants have been conclusively associated to
both diseases with similar effect (such as CARD9) – for genes specifically associated to
only CD (such as NOD2), the UC group is combined with controls (see Anderson et al. 2011
Supplementary Information).
Novel protective splice variant in CARD9
CARD9 has been identified as associated to both CD and UC risk, with a common coding
variant (rs4077515 creating substitution S12N – both alleles roughly equifrequent) that
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represents a ‘typical’ GWAS hit (OR ~ 1.2 in both diseases)8,9. In the pooled sequencing,
we identified a splice site variant in CARD9 (Figure 2, Figure S4) altering the first invariant
base after exon 11 in 6 controls and 0 disease patients, suggesting a potentially strong
protective effect. Follow-up confirms a highly significant association (p<10−16), with the
allele appearing at a frequency of roughly .20% of cases and .64% of controls (OR ~ 0.3,
Table 2, Table S4). While skipping exon 11 places translation out of frame, the resulting
transcript is predicted to escape nonsense mediated decay as premature truncation occurs
close to the final splice junction in exon 12. Indeed this hypothetical transcript (Figure 2,
Figure S4) has actually been observed in spleen, lymph-node and peripheral blood
mononuclear cell (PBMC) derived cDNA libraries. Of note, this rare protective variant
actually occurs on a haplotype carrying the risk allele at S12N, indicating that not only are
the two associations independent but that the splice variant also completely eliminates the
risk normally associated with the common haplotype. Since the CD risk allele at S12N has
been associated with higher expression of CARD9, a consistent allelic series may exist if the
splice variant is much more substantially low or non-functional and therefore highly
protective.
Rare risk variants in NOD2
NOD2, is a member of a family of human cytosolic, non-TIR NACHT-LRR proteins (TIR =
Toll/IL-1 receptor; NACHT = neuronal apoptosis inhibitor protein, MHC class 2
transactivator, HET-E, TP1; LRR = leucine-rich repeats)24 first implicated in CD13,25 and
later discovered to be involved in Blau Syndrome26. The three previously known causal
mutations, R702W, G908R, and fs1007insC, reside in the LRR domain of NOD2, whereas
the mutations identified in Blau Syndrome lie on the highly-conserved NACHT nucleotide
binding domain (NDB).
We identify five distinct rare variants (R311W, S431L, R703C, N852S, and M863V), as
well as several others in LD with one of these, that are independently associated with CD
risk (Table 2, Table S4). S431L (p=.0004) (and the rarer V793M contained on a subset of
S431L haplotypes), R703C (p=2.3×10−5) and N852S (p=1.1×10−6) variants are found on
distinct haplotypes that do not contain the known causal mutations: R702W, G908R,
fs1007insC (Figure 3a, 3b) and are thus completely independent risk variants. R311W
shares a subset of haplotypes with R703C (Figure 2), however conditional analysis and
haplotype testing indicates both alleles likely contribute independently to risk (Table S5).
M863V is a rarer variant that has arisen on the haplotype background of fs1007insC and
while the risk estimate of M863V+fs1007insC is stronger (OR=4.02 [2.8,5.7]) is higher than
the risk attributable to fs1007insC alone (OR=3.16 [2.9,3.4]), the low frequency of M863V
precludes a conclusive statement as to the functionality of M863V at this point – for later
calculations of novel variance explained we do not count this an additional risk factor.
Functional assessment of additional NOD2 associated alleles
Assays to identify the effect of the mutations on NOD2 intracellular localization
demonstrated that S431L and the well-studied insertion mutation (fs1007insC) failed to
localize at the membrane area as opposed to N852S (Figure 4). We next determined the
abilities of NOD2 mutants S431L and N852S to activate NF-kB in response to NOD2 ligand
muramyl dipeptide (MDP). HEK293T cells were transfected with the point mutants as well
as wild type NOD2 and the well-studied fs1007 mutant (Figure 4). Western Blot analysis
showed that the point mutations did not affect expression level compared to the wild type
protein (Figure 4). As published previously, fs1007 mutant failed to induce NF-kB
activation after MDP stimulation. The MDP-induced NF-kB activation was also impaired in
presence of S431L and N852S (Figure 4).
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Together these results indicate that the N852S mutation residing in the LRR domain may
perturb MDP recognition without affecting NOD2 intracellular localization, similarly to the
common mutations R702W and 908R23. This is opposite to the fs1007insC mutation, which
also affects the targeting of NOD2 to the membrane area. Mutation S431L resides in the
Nucleotide binding domain (NDB) of the protein and impaired both localization and MDP-
induced NF-kB activation. These findings are in line with previous studies demonstrating
that critical residues within the NBD region attenuate MDP dependent NF-kB activation24.
Further studies are needed to determine the instructive role of NOD2 mutants in
coordinating autophagy, control of cellular stress signals and adaptive immune responses.
Asn852Ser and Met863Val rare risk variants are more common in Ashkenazi Jewish
individuals
The highest reported prevalence of CD among white individuals is in subjects of Ashkenazi
Jewish (AJ) descent, occurring two to four times more frequently than in non-Jewish white
populations29. Tukel and Shalata et al (2004)30 screened the NOD2 gene for rare variants
and revealed five novel changes (D113N, D357A, I363F, L550V, and N852S) of which
N852S occurred only in AJ individuals and was proposed as potentially disease
predisposing, with 7 transmissions and only 1 non-transmission from heterozygous parents
to affected offspring in an Ashkenazi Jewish family collection – concordant with the case-
control observations in this study. In our study, Ashkenazi Jewish individuals had a much
higher frequency of both N852S and M863V (4%, 2% cases respectively in Jewish samples
and .5% for N852S and M863V in CD non-Jewish case samples) – accounting for the
greater incidence of these alleles in the first replication column of table 2 since NIDDK
studies in particular had a specific and significant Ashkenazi Jewish ascertainment.
We examined the haplotype carrying N852S in Ashkenazi Jewish individuals (easily
determined given the existence of two homozygote cases) and in white non-Jewish
individuals in the subset of samples with existing GWAS genotype data8,9,14,22. We found
that the N852S mutation in Ashkenazi individuals lies on a unique extended haplotype that
extends for several megabases (at least 2 Mb to the left and right). However, N852S
mutation in white non-Jewish individuals does not share the extended background
haplotype. In Ashkenazi individuals the average shared distance between a pair of AJ 852S
chromosomes is at least 4Mb, whereas for a pair of NJ 852S chromosomes is 0.5 Mb (Figure
S5) – suggesting that the variant is reasonably old but a single copy was stochastically
enriched in the recent Ashkenazi bottleneck ~ 25 generations ago.
Rare protective variants in IL23R
We also identified significant protective effects of amino acid substitutions G149R (P value
3.2×10−4) and V362I (P value 1.2×10−5) in IL23R. This confirms recently published
findings32 and is consistent with each of these variants having a protective effect equivalent
to that of the more common R381Q substitution (Table 2, Table S4), although they arose on
different haplotype backgrounds and are in no LD with R381Q. Despite the large follow-up
sample size, we did not find evidence for a protective effect of the previously reported R86Q
variant (31747, 0.94). IL23R signaling is attenuated in Th17 cells generated from healthy
subjects carrying the R381Q substitution leading to a decrease of IL17A secretion in
response to IL-23, indicating that R381Q is associated with reduced Th17 responses33. In
addition, recent studies have highlighted a role for IL23 in Th17 cell lineage commitment in
the absence of TGF-β. This alternate mode of Th17 differentiation, dependent on IL23R
expression, appears to play greater pathogenic role further highlighting the value to
discovering protective variants in autoimmunity31. Future therapies for autoimmune disease
should consider the phenotypic characters of pathogenic Th17 cells, generated in the
absence of TGF-β, and their signaling pathways as possible targets.
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Rare risk and protective variants in IL18RAP, C1orf106, CUL2, MUC19, and PTPN22
Although CD and UC do not share an association to the common variant (rs2058660,
MAF=.23, OR ~ 1.19, chr2:102.17–102.67 Mb), overlap with celiac disease has recently
been documented to rs205866034. We identify a rare risk missense variant, V527L (MAF= .
003), in IL18RAP with an estimated minor allele odds ratio of 2.79 to CD. In addition, a low
frequency missense variant, Y333F (MAF=.008), in C1orf106 was associated to risk both in
CD and UC.
A common CUL2 variant (rs12261843, MAF= 0.30, OR ~ 1.15) has been identified as
associated to both CD and UC risk. In the pooled sequencing experiment we identified a
splice site variant in CUL2 altering a nucleotide 5 bases downstream exon 17 with an
estimated OR of 0.72 in the follow up samples (MAF = .007). Interestingly, several
members of the ubiquitin proteosome are present in the autophagy interaction network
including CUL2 suggesting cross talk between these processes in intracellular quality
control and immunity35.
A common missense variant (risk allele frequency=.90, OR=1.31, rs2476601) in PTPN22 is
associated with CD7,8, Type 1 diabetes (T1D)36, Rheumatoid Arthritis (RA)37, and
Vitiligo38. This is one of the rare instances where the direction of association differs in
different diseases, with the minor allele (W) strongly associated to T1D, RA, and vitiligo but
highly protective against CD. Analysis of rare variants in the IBD versus healthy controls
comparison demonstrates a modest risk effect (P value = .00026, minor allele odds ratio =
1.6), for a rare (MAF = .003) PTPN22 missense mutation (H370N). Ongoing studies in
other autoimmune diseases will help elucidate the overall relevance of H370N and
rs2476601 in different conditions.
Examination of haplotype structure (Figure S6) and formal conditional analysis (Table S6)
demonstrates that the rare variants highlighted in IL18RAP, MUC19, C1orf106, PTPN22,
and CUL2 are independent of the common GWAS variant associated. Specifically, the rare
variants at IL18RAP and MUC19 arise on the common higher risk background but confer
independently significant risk, the rare variants at PTPN22 and C1orf106 occur on the
common low risk background and are therefore obviously independent, and the rare variant
at CUL2 is protective and in weak LD with common risk variants at that locus.
Heritability estimates of rare associated variants
We estimated the fraction of additive genetic variance explained using the liability threshold
model of Pearson and Lee39 and Fisher40, which assumes an additive effect at each locus
and shifts the mean of a normally distributed distribution of disease liability for each
genotype class. We assumed a prevalence of CD of 4 per 1,000 and a total narrow-sense
heritability of 50%41. We estimate that the discovered rare and low frequency variants
associated to CD in this study contribute another 1–2% genetic variance explained over all
populations and 2–3% genetic variance explained to the Ashkenazi Jewish population (Table
S7).
DISCUSSION
Genomewide association has been remarkably successful in IBD with now 99 confirmed
associations already providing important and previously unappreciated views into disease
biology. Oddly however, it is quite often what has not yet been discovered or explained
(perhaps 75% of the heritability) that consumes much of the debate and focus in human
genetics. Next-generation sequencing offers potential insights into both the biology and the
heritable component explained by GWAS results through direct ascertainment of a more
complete allelic spectrum of functional alleles in cases and controls, including rare variation.
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With a targeted, pooled approach, we performed an efficient and cost-effective scan for rare
and low frequency polymorphisms in genes in regions identified as relevant in GWAS. After
extensive follow-up genotyping, we identify highly significant variants at CARD9, NOD2,
CUL2, and IL18RAP that contribute to risk independently from previously defined variants
at these loci, and we demonstrate the functionality of the newly implicated NOD2 variants.
In addition, we report additional protective variants at IL23R, and identify an excess of
additional nominally significant variants in MUC19, PTPN22, and C1orf106.
The results of this experiment are highly relevant to ongoing debates in human genetics.
While we found little support for the hypothesis that common variant associations are
simply an indirect LD-driven byproduct of higher-penetrance rare alleles, additional
independent acting low frequency alleles in genes implicated by common variant association
are documented. In the case of the CARD9 splice variant, this novel allele explains more of
the overall population variance in risk than does the common S12N associated variant
(roughly .3% and .2% respectively). Such observations, should they become commonplace
now that technology permits their discovery, may render pointless the strongly worded
debates over common versus rare variation. As with many quantitative traits and Mendelian
disorders, we observe instances where common alleles of modest effect and rarer alleles
with more significant impact peacefully coexist in the same genes – both types of variation
providing insight into the same disease biology. In fact the value of these results is likely
much more in the realm of functional biology than in nudging the tally of variance explained
marginally forward. In addition to the functional confirmation of NOD2 alleles, the
identification of a novel CARD9 isoform that is strongly protective against disease
development provides a concrete handle with which to study disease biology and potentially
a model that could be mimicked therapeutically. Adding .3% to the variance explained and
an additional tidbit for the discussion of rare variants and GWAS studies (without which
CARD9 would not have been evaluated in this study) are trivial by comparison. Finally, our
study validates the principle that additional variants should be routinely searched for by
thorough sequencing of genes located within significantly associated regions in GWAS in
large sets of cases and appropriate controls.
ONLINE METHODS
DNA preparation and pooling
Crohn’s disease patients and Controls from NIDDK consortium were selected with priority
given to samples with adequate amounts of DNA and those with GWAS data available.
Samples from the NIDDK consortium undergo rigorous clinical phenotyping and control
matching for genetic studies. DNA purification methods are also performed on these
samples. The case/control samples selected have already been stringently matched in
previous GWAS studies. The baseline concentration of genomic DNA was quantified by
Quant-iT™ PicoGreen® dsDNA reagent and detected on the Thermo Scientific Varioskan
Flash. All DNAs were normalized to 20ng/µl and repeat quantification was performed to
assess accuracy of the normalization step. The quantification and normalization was
repeated again to ensure that all samples fell within the desired concentration range. The
normalization steps were done with robotic automation using the Packard Multiprobe II HT
EX. Once each individual sample is normalized to 10ng/ul, groups of 50 individuals were
pooled together using a Multiprobe or Packard Robotic to total 14 pools (700 people).
Target selection and design
Candidate exonic targets from top GWAS published, confirmed genes along with a sample
of other highly significant regions of interest were uploaded against HG17 freeze to an in-
house database, which houses PRIMER3 software. Amplicons encompassing each target
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region (coding exons only) were designed using Illumina parameters including a minimum
amplicon length of 150bp and maximum amplicon length of 600bp with no buffer sequence
added. Additionally, Not1 tails were added to the primer pairs to provide a recognition site
for downstream concatenation and shearing step. Amplicons were validated by running PCR
product on agarose gels to assess clarity of single bands. Amplicons that had 2/3 clear bands
were considered validated. Pfu enzyme, used in Illumina sequencing protocol for PCR, was
used in the characterization process. In total, 593 primer pairs passed and covered 95% of
the 108 kb target. PCRs contained 20 ng of pooled genomic DNA, 1× HotStar buffer, 0.8
mM dNTPs, 2.5 mM MgCl2, 0.2 units of HotStar Enzyme (Qiagen), and 0.25 µM forward
and reverse primers in a 6- or 10-µl reaction volume. PCR cycling parameters were: one
cycle of 95°C for 15 min; 35 cycles of 95°C for 20 s, 60°C for 30 s, and 72°C for 1 min;
followed by one cycle of 72°C for 3 min. Each PCR product was then treated to similar
steps used for the pooling of DNA individuals. The quantification, normalization, and
pooling process was again required to ensure that equimolar PCR product went into library
construction to have equal representation of all targets. PCR yield was assessed by the same
quantification system and the lowest product yield was then used to normalize across PCR
plates. Secondary confirmation was ascertained by testing one column of PCR product per
plate on 2% agarose E-gel against 1kb DNA ladder to visualize PCR product size. The 593
PCR products were then combined, using the Packard Multiprobe II HT EX, resulting in an
amplified target product per sample pool for sequencing.
Sequencing
The PCR products for each pooled sample were concatenated using NotI adapters and
sheared into fragments as previously described42. Libraries were constructed by a modified
Illumina single-end library protocol, with 225–275 bp gel size selection and PCR
enrichment using 14 cycles of PCR, and then single-end sequenced with 76 cycles on an
Illumina Genome Analyzer. Each sample pool was sequenced using a single lane of a
Illumina GAII analyzer flowcell. 76bp, 36bp and 52bp reads were aligned to the genome
using MAQ algorithm43 within the Picard analysis pipeline, and further processed using the
SAMtools software44 and custom scripts.
Genotyping
137 high confidence Single Nucleotide Variants (SNVs) were assayed in two phases of
genotyping using Sequenom MassARRAY iPLEX GOLD chemistry50. The first phase
consisted of 72 SNVs and the second phase of 65 SNVs on 350 NIDDK Crohns samples and
350 NIDDK controls for validation purposes. In each phase of genotyping, oligos were
synthesized and mass-spec QCed at Integrated DNA Techologies. All SNVs were genotyped
in multiplexed pools of 25–36 assays, designed by AssayDesigner v.3.1 software, starting
with 10 ng of DNA per pool. Around 7 nl of reaction was loaded onto each position of a
384-well SpectroCHIP preloaded with 7 nl of matrix (3-hydroxypicolinic acid).
SpectroCHIPs were analyzed in automated mode by a MassArray MALDI-TOF Compact
system 2with a solid phase laser mass spectrometer (Bruker Daltonics Inc.). We obtained
high quality data (>95% genotype call rate, HWE P> 0.001) in all samples that had at least
one SNV. Variants were called by real-time SpectroCaller algorithm, analyzed by
SpectroTyper v.4.0 software and manually reviewed for rare variants. Additional Sequenom
Genotyping was carried out for 9 SNVs in 2887 CD cases and 2244 healthy controls from
the German popgen biobank collection. German patients were recruited either at the
Department of General Internal Medicine of the Christian-Albrechts-University Kiel, the
Charité University Hospital Berlin, through local outpatient services, or nationwide with the
support of the German Crohn and Colitis Foundation. German healthy control individuals
were obtained from the popgen biobank45.
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Beadexpress data generated by the NIDDK IBD consortium on 5549 NIDDK samples aided
in validation purposes as well as follow-up of associated variants. Genotyping of IIBDGC
samples were done with the Illumina Immunochip where design of SNVs discovered in this
experiment were included. Independent Crohn's disease and ulcerative colitis (UC) patients,
along with unaffected population controls were genotyped at five genotyping centers (See
Supplementary Material on quality control steps).
Cells, Antibodies and Plasmids
HEK293T were obtained from American Type Culture Collection (ATCC) and maintained
according to ATCC’s instructions. Anti-β-actin Ab was obtained from SantaCruz. Anti-
NOD2 Ab (clone NOD-15) was obtained from BioLegend.
Human wild type NOD2 cDNA was cloned in pBK-CMV vector (stratagene) to express
untagged NOD2. Mutated constructs were made using the Quick change site-directed
mutagenesis kit (stratagene). Inserts were fully sequenced to check the presence of only the
desired mutations.
Immunostaining
HEK293T were seeded on poly-lysine-coated slides and transfected with NOD2 constructs
using lipofectamine 2000. The following day, cells were fixed with 4% paraformaldehyde
(10 min) and permeabilized PBS-Triton X-100 0.1% (10 min). After washing with PBS, the
sections were incubated 15 minutes in PBS containing 1% bovine serum albumin. The
sections were then incubated with anti-NOD2 Ab (1:200) for one hour, washed using PBS,
incubated with dylight 488 conjugated donkey anti-mouse Ig Ab (Jackson
ImmunoResearch) for one hour, washed using PBS and incubated with PBS containing
100µg/ml of DABCO (Sigma) as antifading reagent before mounting in Glycergel medium
(Dako). Fluorescence signals were captured using a laser confocal microscope (model
Radiance 2000 Bio-Rad).
Luciferase reporter assays
HEK293T cells were co-transfected with 0.025 ng of renilla luciferase plasmid, 2.5 ng of Ig-
pIV firefly luciferase reporter and 5 ng of NOD2 plasmids using Lipofectamine 2000
(Invitrogen). After 24h of transfection, cells were stimulated with MDP-LL or MDP-LD
(1ug/ml) for 6h. Luciferase activities were measured using the Dual Luciferase reporter
assay system (Promega) in a BD moonlight 3010 luminometer (BD Biosciences) and
normalized to the internal transfection control of renilla luciferase activity.
Statistical Methods
Variant Discovery Software—Next generation sequencing technology is allowing
investigators for the first time to comprehensively survey the full spectrum of genetic
variation in large case/control samples. Tools and analytical methods are being developed to
address the rapid change in technology and data application capabilities. We have
implemented methods in the program Syzygy for analysis of pooled sequencing data
generation. The software enables investigators to perform SNP calling on pooled data,
estimate allele frequencies of discovered variants, apply single-marker association test in
pooled setting, group wise testing of rare and low frequency variants discovered, power
evaluation and QC summary, and annotation of variants discovered in regions from primary
sequencing data in BAM/SAM format. By doing so allowing researchers to prioritize
variants and regions for follow up and dissection of the genetic architecture in the targets of
interest.
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Mega-Analysis of Rare Variants—One of the goals of the project was to combine data
from different groups and subpopulations where samples were carefully matched. We
propose the following approach to analyze rare - variants, referred to in this manuscript as
M.A.R.V.
Step 1. Let our random variable
Step 2. The affected/unaffected status is permuted among the individuals within each
subgroup, and Step (1) is repeated k times to sample x1*, …, xk* under the null-
hypothesis.
Step 3. The average (μ̂) and sample standard deviation (σ̂) of x1*, …, xk* are calculated
and the standardized score is found as
Under the null hypothesis, Z has an approximately standard normal distribution (see Figure
S7). Thus, a p-value for the association test can be obtained by comparing Z to the quantiles
of the standard normal. Alternatively, a p-value can be obtained by using a standard
permutation test, where the p-value is found by (k0+1)/(k+1), and k0 is the number of the k
permutations that are at least as extreme as x.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. (a) Schematic overview of the Crohn’s disease rare variant phenotype project. (b)
Power to detect single-marker rare variant association in follow-up sample sets
Here we report the results of the Crohn’s pooled resequencing project with follow up
genotypes in over 13167 CD patients, 12153 UC patients, 15331 healthy controls. We report
that of the 70 markers successfully genotyped 22%,60%,79%,88%,91% have at least 80%
power to detect association at minor allele frequency odds ratios of 1.5,2,3,4, and 5
respectively (Figure 1b,S3a,S3b), implying that we are well positioned to address the
contribution of rare and low frequency polymorphisms in GWAS loci to IBD.
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Figure 2. CARD9 protective splice site variant and predicted transcript
(a) A splice-site variant IVS11+1C>G (OR = 0.29) conferring protection against Crohn’s
disease with predicted transcript. This hypothetical transcript has been observed in spleen,
lymph-node and peripheral blood mononuclear cell (PBMC) derived CDNA libraries. We
predict exon 11 to be skipped and alternative transcript to include exon 9 mRNA sequence
continuing to exon 12 including 21 AA before reaching a premature stop.
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Figure 3. (a) Identification of additional rare variants associated with Crohn’s disease and its
haplotype structure (b) NOD2 haplotypes observed in 700 individuals with overlapping genotype
data (R311W, S431L, R702W, R703C, V793M, N852S, M863V, G908R, fs1007insC)
(a) Five additional risk variants are discovered in NOD2 demonstrating the – log10(P value)
and the minor allele odds ratio with 95% CI along with their haplotype block. (b) Note that
S431L and V793M are in tight LD and we regard this as one unit S431L + V793M, R703C
has a higher frequency than R311W although they share haplotypes conditional analysis
(Table S3) demonstrates independent contributions. M863V lies on the background
haplotype of fs1007insC.
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Figure 4. Functional analyses of NOD2 variants
HEK293T cells were transfected with NOD2 constructs and fixed using paraformaldehyde
4% at 24h post transfection. Cells were then subjected to immunofluorescent staining to
detect NOD2 and fluorescence was collected using a confocal microscope. Image gallery
displays a single confocal section.
HEK293T cells were transfected with NOD2 constructs and reporter plasmids encoding
firefly luciferase cloned under a promoter containing NF-kB elements and with a plasmid
encoding renilla luciferase as a transfection control. After 24h, cells were then stimulated
with MDP-LL or MDP-LD (1ug/ml) for 6h. Transcriptional activation was quantified by
ratios of firefly luciferase activity to renilla luciferase activity. Data were normalized to the
unstimulated condition with empty vector transfection. Statistical analyses were performed
using Student t-test. (* p<0.05). Cell lysates were also collected and subjected to western
blot analysis to detect NOD2 and actin expression levels.
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Table 1
Variant Discovery Summary
Using Syzygy we detected 429 high-confidence variants (240 nonsynonymous sites, 169 synonymous sites,
and 20 variants within 5bp of the nearest splice site) within our 107.5kb targeted region with a dbSNP rate of
45%, nonsynonymous-to-synonymous ratio of 1.42, and transition to transversion ratio of 2.3 in the CD
pooled sequencing experiment with 350 CD patients and 350 healthy controls.
Category High Quality Moderate Quality
Variants Identified 429 173
dbSNP % 45 24
NS/S 1.4 1.7
Ts/Tv 2.3 1.4
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